The biotech companies Evotec and Alloy Therapeutics have agreed on a cooperation with which the Hamburg-based company wants to expand its own antibody research platform: “As part of this agreement, Evotec has access to Alloy’s ATX-Gx mouse platform for the best-in-class In vivo research into fully human monoclonal antibodies (“mAb”) that is used in its own and in partnered R&D projects for more than 15 indications, ”Evotec reported on Monday. According to the North Germans, this should provide numerous starting points for new research programs.
Evotec does not provide financial details of the cooperation agreement today.
“The integration of ATX-Gx (TM) into Evotec’s extensive biologics discovery capabilities will accelerate the translation of therapeutic antibody development programs for Evotec’s scientific clients,” said Errik Anderson, chief executive officer, founder and chairman of Alloy Therapeutics.
Livestream on December 14th, 2020 from 6 p.m .:
With Hans-Werner Sinn, former President of the Ifo Institute: Corona and the miraculous increase in money in Europe
– Here is the stream! –